SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is generating significant social media buzz as traders debate its potential as a high-growth Layer-1 alternative to Solana, with many highlighting its integration into institutional products and recent developments within its ecosystem. Community discussions are split between bullish sentiment fueled by institutional accumulation and skepticism from those wary of market volatility and recent price fluctuations.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The community is actively debating the potential for a breakout or consolidation phase as $PEPE trends alongside broader meme coin volatility. Traders are expressing mixed sentiments, with some focusing on long-term accumulation strategies during pullbacks while others remain skeptical about the coin's price stability.

StupidCoin

StupidCoin is gaining significant traction within the Solana ecosystem as traders rally behind its active community-led development and viral marketing efforts. Enthusiasts are highlighting the project's recent growth, community collaborations, and ecosystem integrations as key drivers for heightened market interest.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is seeing heightened market attention driven by institutional interest following its inclusion in a T. Rowe Price crypto ETF filing, though the community remains sharply divided between long-term holders citing Shibarium utility and skeptics calling the project a stagnant asset. Active discussions are dominated by debates over token burn mechanisms, ongoing layer-2 development, and speculative rotation into smaller meme-themed projects on platforms like Base.

The KARRAT protocol is a decentralized gaming infrastructure layer, supported by $KARRAT and empowered by a truly decentralized community with a shared vision embracing gaming, entertainment and AI products catering for the new era.  To accelerate the evolution of gaming, entertainment, and AI-driven experiences with blockchain technology and a truly empowered community.  The KARRAT protocol pioneers a decentralized framework in gaming and entertainment, combining blockchain with community-driven collaboration. $KARRAT can animate ecosystems of games and products and the protocol makes tools available to support these industries and the adoption of KARRAT technology provides a unique, personalized gaming experience.

KARRAT

KARRAT is gaining community attention as investors anticipate a major breakout driven by its deep integration into the Web3 gaming sector, specifically through the StudioChain infrastructure and its flagship title, My Pet Hooligan. Many participants are actively accumulating tokens, citing strong strategic partnerships with major AI and tech firms as a primary catalyst for long-term growth despite recent market volatility.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is seeing a surge in community discussion following a period of intense volatility and triple-digit gains that have sparked renewed interest among retail traders. While some investors are highlighting the potential for future growth and technical breakouts, others remain skeptical, debating whether the movement represents a genuine turnaround or just another speculative pump.

Centrifuge

Centrifuge is attracting significant investor attention as a key player in the Real World Assets sector, bolstered by institutional partnerships with major financial firms and its integration into popular ecosystems like Base. The community is actively discussing its potential for tokenized finance and the role of its infrastructure in bridging traditional credit markets with decentralized finance.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant investor attention following a positive final pre-BLA meeting with the FDA for sonelokimab in hidradenitis suppurativa, which de-risked the regulatory path toward a planned BLA submission. The community is actively discussing the drug's potential for best-in-class efficacy, durability, and commercial differentiation compared to incumbents, with traders closely monitoring upcoming phase 3 readouts and long-term data as catalysts for a potential revaluation or M&A activity.

Solana is a high-performance Layer 1 blockchain designed for mass adoption by providing a fast, secure, and low-cost environment for decentralized applications. It distinguishes itself by scaling globally without the use of complex sharding or multiple layers, instead maintaining a single, unified ledger to avoid liquidity fragmentation. This architecture allows it to process thousands of transactions per second with sub-second finality, often at a cost of less than a penny per transaction.  The network operates on a unique hybrid model that combines Proof of Stake with an innovation called Proof of History, which functions as a decentralized clock to timestamp transactions. This system reduces the need for constant node communication, allowing the Sealevel engine to run non-conflicting smart contracts in parallel across multiple CPU cores. Further efficiency is gained through the Gulf Stream protocol, which reduces confirmation times by forwarding transactions to validators before the current block is finished.  Founded in 2017 by Anatoly Yakovenko, Solana is now supported by the Switzerland-based Solana Foundation and significant institutional investors like Andreessen Horowitz and Polychain Capital. The platform’s native token, SOL, serves as the primary currency for paying transaction fees, participating in network governance, and securing the system through staking.   Solana has also seen significant institutional adoption ranging from spot Solana ETFs to major partnerships including Visa's 2025 launch of USDC settlement on the network and the tokenization of public equity by firms like Galaxy Digital.

Solana

Solana is capturing significant community attention as traders highlight its ecosystem growth, including new protocol integrations and increased staking engagement, while speculative interest in various meme tokens on the chain drives high social media activity. Market participants remain focused on potential price breakouts, with many actively debating whether upcoming macro developments will fuel a sustained move toward higher valuation levels.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following the announcement of a pivotal Phase 3 design for its lead drug candidate, CAD-1005, aimed at treating heparin-induced thrombocytopenia. While some investors are optimistic about the upcoming trial path and orphan drug designation, the community is currently debating the stock's volatility and widespread skepticism surrounding the heavy automated bot activity on discussion boards.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Alnylam to Webcast Presentations at Upcoming Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences: BofA Securities Healthcare Conference on Wednesday, May 13, 2026, at 10:40 am PT (1:40 pm ET) in Las...

Bronte Capital Management Pty Ltd. Has $15.45 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Bronte Capital Management Pty Ltd. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 11.1% in the 4th quarter, according to the company in its most recent filing...

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type...

PFA Pension Forsikringsaktieselskab Buys Shares of 35,405 Alnylam Pharmaceuticals, Inc. $ALNY

PFA Pension Forsikringsaktieselskab bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 35,405 shares of the biopharmaceutical company's stock, v...

PKO Investment Management Joint Stock Co Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

PKO Investment Management Joint Stock Co boosted its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 750.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,800 shares of the biopharmaceutical company's stock afte...

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Kornitzer Capital Management Inc. KS

Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 53.1% during the fourth quarter, according to its most recent Form...

Royal Bank Of Canada Has Lowered Expectations for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Royal Bank Of Canada lowered their price objective on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an "outperform" rating for the company in a research report on Friday...

Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth

ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.

Wells Fargo & Company Issues Positive Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an "equal weight" rating in a research note on Friday...

Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Jennison Associates LLC

Jennison Associates LLC trimmed its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.9% in the fourth quarter, according to its most recent disclosure with the Securities...

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002, and is headquartered in Cambridge, MA.

Alnylam Pharmaceuticals Inc

Up > 1%

Flat +/- 1%

Down > 1%

Where does the $SPY finish next week vs. Friday’s close?

Current Price	$295.05
Prev Close	$295.91
Open	$295.91
Dividend Yield	0.00%
50-Day Moving Average	$316.38
Beta	0.84
Avg. Volume	1.11M
PE Ratio	70.10

52-Week High	$495.55
52-Week Low	$252.79
Market Capitalization	$39.39B
EPS (Annual)	$2.33
Price to Book	36.61
Revenue Per Employee	$1.49M

ALNY
Alnylam Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALNY News

ALNYAlnylam Pharmaceuticals Inc